Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)†
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)†
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 25, Issue 5, Pages 1018-1025
Publisher
Oxford University Press (OUP)
Online
2014-03-01
DOI
10.1093/annonc/mdu088
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patients’ perspectives on palliative chemotherapy of colorectal and non - colorectal cancer: a prospective study in a chemotherapy- experienced population
- (2013) Marika Mende et al. BMC CANCER
- Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients WithKRASWild-Type Unresectable Colorectal Liver-Limited Metastases
- (2013) Le-Chi Ye et al. JOURNAL OF CLINICAL ONCOLOGY
- A Systematic Review of Repeat Hepatectomy for Recurrent Colorectal Liver Metastases
- (2013) Vincent W. T. Lam et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- (2012) Kjell Magne Tveit et al. JOURNAL OF CLINICAL ONCOLOGY
- Patients' Expectations about Effects of Chemotherapy for Advanced Cancer
- (2012) Jane C. Weeks et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Prognostic models for outcome following liver resection for colorectal cancer metastases: A systematic review
- (2011) L. Spelt et al. EJSO
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Richard A Adams et al. LANCET ONCOLOGY
- Surgical management and outcomes of colorectal cancer liver metastases
- (2010) E. J. A. Morris et al. BRITISH JOURNAL OF SURGERY
- Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer
- (2009) Myrddin Rees et al. ANNALS OF SURGERY
- Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
- (2009) Benoist Chibaudel et al. JOURNAL OF CLINICAL ONCOLOGY
- Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?
- (2009) René Adam et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
- (2009) Gunnar Folprecht et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started